Patent · US Active

Compositions and methods for inhibition of the JAK pathway

US9084795B2 · kind B2 · utility

2Cited by

9References

19Claims

0Family size

Assignee

Rigel Pharmaceuticals, Inc. · US

Inventors

Hui Li · Santa Clara, US
Thilo J. Heckrodt · San Francisco, US
Yan Chen · Sunnyvale, US
Vanessa Taylor · San Francisco, US
Rajinder Singh · Belmont, US
Pingyu Ding · Foster City, US
Rose Yen · San Francisco, US

Key dates

Filing date	Jul 16, 2013
Grant date	Jul 21, 2015
Priority date	—
Expiry date	Jul 16, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07F9/65583
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.